Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.
about
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Phase I study of the investiga ...... s with advanced solid tumours.
@en
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib
@nl
type
label
Phase I study of the investiga ...... s with advanced solid tumours.
@en
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib
@nl
prefLabel
Phase I study of the investiga ...... s with advanced solid tumours.
@en
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib
@nl
P2093
P2860
P1433
P1476
Phase I study of the investiga ...... s with advanced solid tumours.
@en
P2093
Aaron Enke
Chirag Patel
Fabian Zohren
Gerald S Falchook
Kathleen N Moore
Manish R Patel
Rachel Neuwirth
Swapan Chowdhury
Todd M Bauer
P2860
P304
P356
10.1136/ESMOOPEN-2017-000291
P577
2018-02-01T00:00:00Z